SCHEMBL5264473

SCHEMBL5264473

CCOC(=O)N1CCN(c2nc(=O)c3c(C)c(OC)c(OC)cc3[nH]2)CC1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 5/20 0.44
▸ PDE3B Q13370 1/20 0.42
▸ PDE3A Q14432 1/20 0.42
▸ HTT P42858 2/20 0.41
▸ USP2 O75604 1/20 0.41
▸ ALDH1A1 P00352 7/20 0.41
▸ POLB P06746 2/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ HSD17B10 Q99714 2/20 0.41
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ HPGD P15428 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ GAA P10253 2/20 0.40
▸ TSHR P16473 2/20 0.40
▸ ALOX15 P16050 1/20 0.40
▸ LMNA P02545 1/20 0.40
▸ IDE P14735 1/20 0.40
▸ HIF1A Q16665 1/20 0.40
▸ HTR1A P08908 1/20 0.39
▸ ADRA2C P18825 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5260022 0.93 MAPT (0.45) MAPTPDE3BPDE3AHTTUSP2
SCHEMBL5262020 0.89 LMNA (0.39) MAPTHTTALDH1A1POLBSMN1; SMN2
SCHEMBL5260904 0.87 HTR1A (0.39) PDE3BPDE3AALDH1A1POLBHSD17B10
SCHEMBL5263193 0.85 KDM4E (0.48) MAPTHTTALDH1A1POLBCYP2C19
SCHEMBL5260416 0.84 KDM4E (0.40) MAPTHTTUSP2ALDH1A1POLB
SCHEMBL5263197 0.83 CFD (0.43) MAPTHTTALDH1A1POLBHSD17B10
SCHEMBL5259657 0.81 AKR1C3 (0.41) MAPTHTTALDH1A1HSD17B10HPGD
SCHEMBL5262874 0.81 ALDH1A1 (0.55) MAPTALDH1A1HSD17B10SMN1; SMN2HPGD
SCHEMBL5264229 0.80 ALDH1A1 (0.39) PDE3BPDE3AALDH1A1POLBHSD17B10
SCHEMBL5262125 0.80 KMT2A (0.40) MAPTHTTALDH1A1POLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124607-A1 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists ROCHE PALO ALTO LLC 2005-06-09 — — US claimed
EP-1644343-B1 5-SUBSTITUTED QUINAZOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2007-07-04 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124607-A1 5-Substituted quinazolinone compounds useful as alpha 1A/B adrenergic receptor antagonists ADRB1, ADRA1B, ADRB2 MAPT 4009/4885PDE3B 598/4885PDE3A 860/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback